Showing 4461-4470 of 9153 results for "".
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- New From Neocutis: Meet the Micro-Riche Linehttps://practicaldermatology.com/news/new-from-neocutis-meet-the-micro-riche-line/2458420/NEOCUTIS is rolling out a new line. The MICRO-RICHE ultra-hydrating line will expand the company’s MICRO-PROTEIN Complex (MPC) product line. The new MICRO-RICHE line includes more emollient versions of MICRO-NIGHT and MICRO-EYE to keep skin nourished and hydrated as winter approache
- Beauty Business to Go Green with New Master Class, Institutehttps://practicaldermatology.com/news/beauty-business-to-go-green-with-new-master-class-institute/2458421/The newly formed National Beauty Science Institute (NBSI) aims to promote sustainability, authenticity and green energy in the beauty business. The group will hold its first Master Class in April 2017 to educate students and consumers on the science and sustainability of beauty – a
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- National Rosacea Society Awards Three New Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-three-new-grants/2458430/The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an associate professor of dermatology at Johns Hopk
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- Is Bigger Better? Group Practices Become the New Normhttps://practicaldermatology.com/news/group-practices-are-the-new-norm/2458438/Group physician practices are the new normal, and it seems that dermatologists were ahead of the consolidation curve, according to research in the September 2016 issue of Health Affairs. Researchers examined physician consolidation for both primary care provide
- GLOWBIOTICS MD is New Name of mybody Probiotic Skincarehttps://practicaldermatology.com/news/glowbiotics-md-is-new-name-of-mybody-probiotic-skincare/2458440/GLOWBIOTICS MD is the new name of mybody Probiotic Skincare. Currently carried in over 1,000 doctors’ offices across the country and internationally, the five-year-old brand is the first medical-grade
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).